Vaccitech Australia

Barinthus Biotherapeutics, formerly known as Vaccitech, is a clinical-stage biopharmaceutical company specializing in the development of novel T cell-stimulating immunotherapies. The company's proprietary technology platforms, including ChAdOx and MVA viral vectors and the SNAP synthetic platform, are designed to induce high-quality, antigen-specific T cell responses to treat chronic infectious diseases and cancer. Its lead programs include VTP-300 for the treatment of chronic Hepatitis B and VTP-200 for persistent high-risk HPV infections. Vaccitech Australia Pty Ltd is the company's Australian subsidiary, which facilitates clinical development and regulatory activities within the region. The company was originally spun out of the University of Oxford's Jenner Institute and is headquartered in the United Kingdom.